Literature DB >> 26605318

Raising the bar: optimizing combinations of targeted therapy and immunotherapy.

Alexandre Reuben1, Jacob Austin-Breneman1, Jennifer A Wargo1, Zachary A Cooper1.   

Abstract

Year:  2015        PMID： 26605318      PMCID： PMC4630548          DOI： 10.3978/j.issn.2305-5839.2015.10.28

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

3.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Authors:  Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

4.  MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.

Authors:  Laura J Vella; Anupama Pasam; Nektaria Dimopoulos; Miles Andrews; Ashley Knights; Anne-Laure Puaux; Jamila Louahed; Weisan Chen; Katherine Woods; Jonathan S Cebon
Journal:  Cancer Immunol Res       Date:  2014-01-17       Impact factor: 11.151

5.  Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.

Authors:  Siwen Hu-Lieskovan; Stephen Mok; Blanca Homet Moreno; Jennifer Tsoi; Lidia Robert; Lucas Goedert; Elaine M Pinheiro; Richard C Koya; Thomas G Graeber; Begoña Comin-Anduix; Antoni Ribas
Journal:  Sci Transl Med       Date:  2015-03-18       Impact factor: 17.956

6.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.

Authors:  Richard C Koya; Stephen Mok; Nicholas Otte; Kevin J Blacketor; Begonya Comin-Anduix; Paul C Tumeh; Aspram Minasyan; Nicholas A Graham; Thomas G Graeber; Thinle Chodon; Antoni Ribas
Journal:  Cancer Res       Date:  2012-06-12       Impact factor: 12.701

Review 9.  Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?

Authors:  Inge Marie Svane; Els M Verdegaal
Journal:  Cancer Immunol Immunother       Date:  2014-08-07       Impact factor: 6.968

10.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.